Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05298293 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Electronic MonitorIng of Events for dIffuse Large b Cell LYmphoma

Study acronym: EMILY
StatusNot Yet Recruiting
PhaseNot applicable
SponsorWeprom
Started2022-07-01
View on ClinicalTrials.gov ↗
Diffuse large B cell lymphoma is the most common malignant lymphoid hemopathy. More than half of the patients will be cured with an RCHOP-type immunochemotherapy protocol (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone). Monitoring of adverse effects, risk of relapse and quality of life are essential in overall management. Patients are the best candidates to report them. Managing these events should improve quality of life and reduce costs. The aim of this study is to assess the feasibility of monitoring these events by a web application (Oncolaxy©) and to compare it with a control population in the context of a randomized pilot study including 80 patients per arm with diffuse large cell B lymphoma in first-line treatment with R-CHOP.

Amendment record

Amended once since 2022-03-16. Every amendment is listed below.

Dates here are the day the sponsor filed the amendment, not the day ClinicalTrials.gov published it. Version history last read from ClinicalTrials.gov on 2026-08-30.

2022-03-25
Amendment Study Status, Outcome Measures v1
2022-03-16
Original filing
Trial Details
NCT Number NCT05298293
Lead Sponsor Weprom
Collaborators: Resilience, Incyte Corporation
Conditions Diffuse Large B Cell Lymphoma
Enrollment 160 participants
Start Date 2022-07-01
Primary Completion 2026-12-01 (estimated)
Study Completion 2026-12-01 (estimated)
Updated on ClinicalTrials.gov 2022-04-05